-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascendiant Capital Initiates Coverage On Aytu BioPharma with Buy Rating, Announces Price Target of $12

Benzinga·06/30/2025 10:34:16
Listen to the news
Ascendiant Capital analyst Edward Woo initiates coverage on Aytu BioPharma (NASDAQ:AYTU) with a Buy rating and announces Price Target of $12.